

Gee J, Naleway A, Shui I, Baggs J, Yinc R, Lic R, Kulldorff, M, Lewis E, Fireman B, Daley, MF, Klein NP, Weintraub ES. **Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink**, Vaccine 2011 Oct 26;Vol 29, Issue 46: 8279-8284

- Study was only for 3 years.
- Dr. Klein has received research support from GlaxoSmithKline, Merck & Co., SanofiPasteur, Wyeth (Pfizer), and Novartis;
- Dr. Naleway has received funding from GlaxoSmithKline for a study of cervical procedures
- Mr. Lewis in the past 3 years has worked on grants funded by Merck & Co., Wyeth(Pfizer), Novartis, SanofiPasteur, GlaxoSmithKline, and MedImmune (now AstraZeneca).

Note: GlaxoSmithKline are the makers of Cervarix. Merck & Co. are the makers of Gardasil.

The other authors have indicated they have no financial conflicts of interest.

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua J, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. **Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine**. JAMA 2009 Aug 10;302(7):750-7.

- Financial Disclosures: None reported.
- Funding/Support: The study was implemented by the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA). The only funds used were from CDC and FDA budgets. This study had no external sponsors.